Literature DB >> 26959877

The CHRM3 gene is implicated in abnormal thalamo-orbital frontal cortex functional connectivity in first-episode treatment-naive patients with schizophrenia.

Q Wang1, W Cheng2, M Li3, H Ren1, X Hu4, W Deng1, X Ma5, L Zhao5, Y Wang5, B Xiang1, H-M Wu3, P C Sham3, J Feng2, T Li1.   

Abstract

BACKGROUND: The genetic influences in human brain structure and function and impaired functional connectivities are the hallmarks of the schizophrenic brain. To explore how common genetic variants affect the connectivities in schizophrenia, we applied genome-wide association studies assaying the abnormal neural connectivities in schizophrenia as quantitative traits.
METHOD: We recruited 161 first-onset and treatment-naive patients with schizophrenia and 150 healthy controls. All the participants underwent scanning with a 3 T-magnetic resonance imaging scanner to acquire structural and functional imaging data and genotyping using the HumanOmniZhongHua-8 BeadChip. The brain-wide association study approach was employed to account for the inherent modular nature of brain connectivities.
RESULTS: We found differences in four abnormal functional connectivities [left rectus to left thalamus (REC.L-THA.L), left rectus to right thalamus (REC.L-THA.R), left superior orbital cortex to left thalamus (ORBsup.L-THA.L) and left superior orbital cortex to right thalamus (ORBsup.L-THA.R)] between the two groups. Univariate single nucleotide polymorphism (SNP)-based association revealed that the SNP rs6800381, located nearest to the CHRM3 (cholinergic receptor, muscarinic 3) gene, reached genomic significance (p = 1.768 × 10-8) using REC.L-THA.R as the phenotype. Multivariate gene-based association revealed that the FAM12A (family with sequence similarity 12, member A) gene nearly reached genomic significance (nominal p = 2.22 × 10-6, corrected p = 0.05).
CONCLUSIONS: Overall, we identified the first evidence that the CHRM3 gene plays a role in abnormal thalamo-orbital frontal cortex functional connectivity in first-episode treatment-naive patients with schizophrenia. Identification of these genetic variants using neuroimaging genetics provides insights into the causes of variability in human brain development, and may help us determine the mechanisms of dysfunction in schizophrenia.

Entities:  

Keywords:  First-episode patients; functional connectivity; genome-wide association studies; schizophrenia

Mesh:

Substances:

Year:  2016        PMID: 26959877     DOI: 10.1017/S0033291716000167

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  11 in total

1.  GWAS and systems biology analysis of depressive symptoms among smokers from the COPDGene cohort.

Authors:  Jonathan T Heinzman; Karin F Hoth; Michael H Cho; Phuwanat Sakornsakolpat; Elizabeth A Regan; Barry J Make; Gregory L Kinney; Frederick S Wamboldt; Kristen E Holm; Nicholas Bormann; Julian Robles; Victor Kim; Anand S Iyer; Edwin K Silverman; James D Crapo; Shizhong Han; James B Potash; Gen Shinozaki
Journal:  J Affect Disord       Date:  2018-09-07       Impact factor: 4.839

2.  Integration of methylation QTL and enhancer-target gene maps with schizophrenia GWAS summary results identifies novel genes.

Authors:  Chong Wu; Wei Pan
Journal:  Bioinformatics       Date:  2019-10-01       Impact factor: 6.937

3.  Differences Between Schizophrenic and Normal Subjects Using Network Properties from fMRI.

Authors:  Youngoh Bae; Kunaraj Kumarasamy; Issa M Ali; Panagiotis Korfiatis; Zeynettin Akkus; Bradley J Erickson
Journal:  J Digit Imaging       Date:  2018-04       Impact factor: 4.056

4.  Salivary Flow Alteration in Patients Undergoing Treatment for Schizophrenia: Disease-Drug-Target Gene/Protein Association Study for Side-effects.

Authors:  Anusa Arunachalam Mohandoss; Rooban Thavarajah
Journal:  J Oral Biol Craniofac Res       Date:  2019-06-15

5.  The common variants implicated in microstructural abnormality of first episode and drug-naïve patients with schizophrenia.

Authors:  H Y Ren; Q Wang; W Lei; C C Zhang; Y F Li; X J Li; M L Li; W Deng; C H Huang; F Du; L S Zhao; Y C Wang; X H Ma; X Hu; T Li
Journal:  Sci Rep       Date:  2017-09-18       Impact factor: 4.379

6.  Constitutional 763.3 Kb chromosome 1q43 duplication encompassing only CHRM3 gene identified by next generation sequencing (NGS) in a child with intellectual disability.

Authors:  Xiaofei Cheng; Qifang Yang; Jun Liu; Juan Ye; Huiying Xiao; Gaimei Zhang; Yuanyuan Pan; Xia Li; Ruifeng Hao; Yinfeng Li
Journal:  Mol Cytogenet       Date:  2019-04-17       Impact factor: 2.009

7.  Genome-wide association analysis reveals KCTD12 and miR-383-binding genes in the background of rumination.

Authors:  Nora Eszlari; Andras Millinghoffer; Peter Petschner; Xenia Gonda; Daniel Baksa; Attila J Pulay; János M Réthelyi; Gerome Breen; John Francis William Deakin; Peter Antal; Gyorgy Bagdy; Gabriella Juhasz
Journal:  Transl Psychiatry       Date:  2019-03-18       Impact factor: 6.222

8.  A Novel 16-Genes Signature Scoring System as Prognostic Model to Evaluate Survival Risk in Patients with Glioblastoma.

Authors:  Zunpeng Yu; Manqing Du; Long Lu
Journal:  Biomedicines       Date:  2022-01-29

Review 9.  Integrative omics of schizophrenia: from genetic determinants to clinical classification and risk prediction.

Authors:  Fanglin Guan; Tong Ni; Weili Zhu; L Keoki Williams; Long-Biao Cui; Ming Li; Justin Tubbs; Pak-Chung Sham; Hongsheng Gui
Journal:  Mol Psychiatry       Date:  2021-06-30       Impact factor: 15.992

10.  A regulatory variant of CHRM3 is associated with cannabis-induced hallucinations in European Americans.

Authors:  Zhongshan Cheng; Chureerat Phokaew; Yi-Ling Chou; Dongbing Lai; Jacquelyn L Meyers; Arpana Agrawal; Lindsay A Farrer; Henry R Kranzler; Joel Gelernter
Journal:  Transl Psychiatry       Date:  2019-11-18       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.